CRIS Current Research Information System

RICCI, ANGELA DALIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.748
NA - Nord America 2.141
EU - Europa 1.296
AF - Africa 143
SA - Sud America 135
OC - Oceania 4
Totale 6.467
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.115
SG - Singapore 838
CN - Cina 676
VN - Vietnam 622
IT - Italia 242
SE - Svezia 210
HK - Hong Kong 199
DE - Germania 178
GB - Regno Unito 127
IN - India 102
KR - Corea 100
BR - Brasile 96
IE - Irlanda 96
CH - Svizzera 86
FI - Finlandia 82
NL - Olanda 79
FR - Francia 71
RU - Federazione Russa 57
CI - Costa d'Avorio 44
JP - Giappone 35
SC - Seychelles 32
ID - Indonesia 30
JO - Giordania 24
TG - Togo 22
PH - Filippine 21
AR - Argentina 16
NG - Nigeria 16
AT - Austria 15
TH - Thailandia 15
BD - Bangladesh 14
CA - Canada 14
IQ - Iraq 14
TR - Turchia 13
BG - Bulgaria 12
ZA - Sudafrica 11
ES - Italia 8
MX - Messico 7
PL - Polonia 7
EC - Ecuador 6
PS - Palestinian Territory 6
PY - Paraguay 6
BE - Belgio 5
LT - Lituania 5
MY - Malesia 5
PK - Pakistan 5
UA - Ucraina 5
UZ - Uzbekistan 5
CL - Cile 4
AE - Emirati Arabi Uniti 3
CO - Colombia 3
KE - Kenya 3
MA - Marocco 3
SA - Arabia Saudita 3
TW - Taiwan 3
VE - Venezuela 3
AL - Albania 2
AO - Angola 2
AU - Australia 2
AZ - Azerbaigian 2
CD - Congo 2
DZ - Algeria 2
IL - Israele 2
LB - Libano 2
NP - Nepal 2
NZ - Nuova Zelanda 2
RS - Serbia 2
AM - Armenia 1
CG - Congo 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EG - Egitto 1
ET - Etiopia 1
GE - Georgia 1
HR - Croazia 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
NI - Nicaragua 1
PT - Portogallo 1
RO - Romania 1
SI - Slovenia 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 6.467
Salva come PNG Salva come JPEG
Città #
Singapore 588
Ashburn 220
Dallas 208
Hefei 205
Chandler 204
San Jose 193
Hong Kong 188
Ho Chi Minh City 169
Hanoi 146
Beijing 98
Santa Clara 98
Princeton 97
Dublin 94
Seoul 87
Bern 83
Southend 81
Bologna 79
Council Bluffs 76
Boardman 74
Fairfield 73
Helsinki 61
Lauterbourg 50
New York 47
Los Angeles 45
Abidjan 44
Houston 32
Redondo Beach 28
Seattle 28
Berlin 25
Florence 25
Haiphong 25
Amman 24
Frankfurt am Main 24
Lomé 22
Da Nang 21
Tokyo 20
Buffalo 19
Bengaluru 18
Redmond 17
Cambridge 16
Jakarta 16
Munich 16
São Paulo 16
London 15
Wilmington 15
Lappeenranta 14
San Diego 14
Woodbridge 14
Shanghai 12
Abeokuta 11
Can Tho 11
Milan 11
Turin 11
Sofia 10
Amsterdam 9
Chicago 9
Rome 9
Bühl 8
Nuremberg 8
Tongling 8
Vienna 8
Boydton 7
Des Moines 7
Guangzhou 7
Hyderabad 7
Hải Dương 7
Ninh Bình 7
Orem 7
Stockholm 7
Turku 7
Xi'an 7
Ann Arbor 6
Biên Hòa 6
Falkenstein 6
Jinan 6
Olalla 6
Shenzhen 6
Ankara 5
Brussels 5
Cape Town 5
Forlì 5
Groningen 5
Halhul 5
Harbin 5
Istanbul 5
Medford 5
Montreal 5
Poplar 5
Quận Bình Thạnh 5
San Francisco 5
Siena 5
Tianjin 5
Warsaw 5
Yubileyny 5
Zhengzhou 5
Atlanta 4
Baghdad 4
Boston 4
Bắc Giang 4
Changsha 4
Totale 4.113
Salva come PNG Salva come JPEG
Nome #
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 301
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 230
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 207
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 204
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 200
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 198
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 197
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 194
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 164
Bone targeting agents in patients with metastatic prostate cancer: State of the art 157
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma 157
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 157
Hacking pancreatic cancer: Present and future of personalized medicine 157
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? 140
Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis 138
Landscape and future perspectives of immunotherapy in neuroendocrine neoplasia 136
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue 130
Experimental HER2- targeted therapies for biliary tract cancer 127
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 125
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 124
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 123
The functioning side of the pancreas: a review on insulinomas 119
Tumor-associated macrophages and inflammatory microenvironment in gastric cancer: Novel translational implications 118
Novel HER2-directed treatments in advanced gastric carcinoma: Another paradigm shift? 108
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 106
The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy Among Patients with Urothelial Carcinoma: A Meta-Analysis 101
Nivolumab: an investigational agent for the treatment of biliary tract cancer 101
Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma 100
Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data 99
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials 98
Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study 98
Combination therapy of dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer 89
Recurrent Uterine Smooth-Muscle Tumors of Uncertain Malignant Potential (STUMP): State of The Art 88
Circulating tumor DNA in biliary tract cancer: Current evidence and future perspectives 88
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue 86
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 83
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma 83
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer 75
Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives 74
Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future 72
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? 68
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives 65
The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): A new Pandora's box? 64
Performance and clinical utility of two targeted multigene panels for GIST molecular characterization 64
Pd‐l1, tmb, msi, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer 63
Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look 62
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: A meta-analysis 60
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? 58
Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand? 57
Atezolizumab in advanced hepatocellular carcinoma: Good things come to those who wait 56
Precision oncology in cholangiocarcinoma: current issues in clinical trial design and access to targeted therapies 53
Recent advances of immunotherapy for biliary tract cancer 51
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma 51
First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges 51
DNA damage response alterations in gastric cancer: Knocking down a new wall 49
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects 49
In Regard to “A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)” 48
Systemic adjuvant treatment in hepatocellular carcinoma: Tempted to do something rather than nothing 45
Toward personalized therapy for cholangiocarcinoma: new insights and challenges 43
Radiofrequency ablation for intrahepatic cholangiocarcinoma: a tool upon the path of integrative modalities? 43
Regarding “HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer” 37
Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis 30
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study 25
Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis 22
Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma 22
Immune-based combinations for advanced hepatocellular carcinoma: Shaping the direction of first-line therapy 19
Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine 18
Totale 6.625
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.341
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.341
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202139 0 0 0 0 0 0 0 0 0 13 4 22
2021/2022596 13 4 8 13 18 5 12 42 168 52 172 89
2022/20231.074 84 115 43 102 77 117 36 62 179 56 77 126
2023/2024309 58 41 20 22 25 50 20 20 6 27 11 9
2024/20251.284 61 190 151 102 142 61 76 44 13 93 99 252
2025/20263.209 321 389 469 229 311 140 323 168 630 229 0 0
Totale 6.625